The current state of the art for biological therapies and new small molecules in inflammatory bowel disease - ScienceDirect
Frontiers | The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
Frontiers | Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
Journal of Prescribing Practice - Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease
The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort | Scientific Reports
PDF) Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Advances in Clinical and Experimental Medicine
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting | International Journal of Colorectal Disease
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records | Upsala Journal of Medical Sciences
PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Frontiers | Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch's postulates
Frontiers | Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cureus | Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options? | Article
Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
View of Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records | Upsala Journal of Medical Sciences
Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing
Frontiers | Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence
PDF) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Frontiers | Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
Journal of Prescribing Practice - Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management | Journal of Crohn's and Colitis | Oxford Academic
Frontiers | Dehydrocostus Lactone Suppresses Dextran Sulfate Sodium-Induced Colitis by Targeting the IKKα/β-NF-κB and Keap1-Nrf2 Signalling Pathways
Constipation in ulcerative colitis: pathophysiology and practical management | Frontline Gastroenterology
Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies - Calméjane - United European Gastroenterology Journal - Wiley Online Library
Frontiers | Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study
